Skip to main content
SpringerLink
Log in

Cardiac safety similar with trasuzumab biosimilar and Herceptin

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kolberg HC, et al. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. Drug Safety : 11 Jan 2020. Available from: URL: http://doi.org/10.1007/s40264-019-00886-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cardiac safety similar with trasuzumab biosimilar and Herceptin. Reactions Weekly 1788, 3 (2020). https://doi.org/10.1007/s40278-020-74126-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-74126-9

Search

Navigation